Figure 6
From: SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patients
Total STAT6 and phosphorylated STAT6 (pSTAT6) levels in cultured PBMCs of MS patients compared to normal subjects. PBMCs from MS patients and normal controls were fixed, permeabilized, and stained with antibodies against either total STAT6 (unphosphorylated plus phosphorylated STAT6) or pSTAT6. The histogram overlays are labeled as follows: filled histogram for isotype control, solid line for normal subject, and dashed line for MS patient. (a) The representative levels of total STAT6 in MS patients and normal subjects are shown after quantification with intracellular flow cytometry. (b) The levels of tSTAT6 were quantified based on the relative MFI in PBMCs of MS patients (n=9) and normal subjects (n=8) before and after treatment with IL-4. (c) The representative levels of pSTAT6 in MS patients and normal subjects are shown. (d) The levels of pSTAT6 were quantified based on the relative MFI in PBMCs of MS patients (n=16) and normal subjects (n=13) before and after treatment with IL-4 (*significance of P<0.05).
